PDF(Pubmed)
Abstract：
UNASSIGNED: Chronic kidney disease (CKD) is a major global health concern with increasing prevalence and associated complications. Metabolic syndrome (MetS) has been linked to CKD, but the evidence remains inconsistent. We conducted a systematic review and meta-analysis to investigate the association between MetS and kidney dysfunction.
UNASSIGNED: We conducted a comprehensive search of databases until December 2022 for cohort studies assessing the association between MetS and incident kidney dysfunction. Meta-analysis was performed using fixed and random effects models. Subgroup analyses were conducted to explore heterogeneity. Publication bias was assessed using Egger\'s and Begg\'s tests.
UNASSIGNED: A total of 24 eligible studies, involving 6,573,911 participants, were included in this meta-analysis. MetS was significantly associated with an increased risk of developing CKD (OR, 1.42; 95% CI, 1.28, 1.57), albuminuria or proteinuria (OR, 1.43; 95% CI, 1.10, 1.86), and rapid decline in kidney function (OR, 1.25; 95% CI, 1.07, 1.47). Subgroup analyses showed a stronger association as the number of MetS components increased. However, gender-specific subgroups demonstrated varying associations.
UNASSIGNED: Metabolic syndrome is a significant risk factor for kidney dysfunction, requiring close renal monitoring. Lifestyle changes and targeted interventions may help reduce CKD burden. Further research is needed to understand the connection fully and assess intervention efficacy.
UNASSIGNED: The online version contains supplementary material available at 10.1007/s40200-023-01348-5.
UNASSIGNED: We conducted a comprehensive search of databases until December 2022 for cohort studies assessing the association between MetS and incident kidney dysfunction. Meta-analysis was performed using fixed and random effects models. Subgroup analyses were conducted to explore heterogeneity. Publication bias was assessed using Egger\'s and Begg\'s tests.
UNASSIGNED: A total of 24 eligible studies, involving 6,573,911 participants, were included in this meta-analysis. MetS was significantly associated with an increased risk of developing CKD (OR, 1.42; 95% CI, 1.28, 1.57), albuminuria or proteinuria (OR, 1.43; 95% CI, 1.10, 1.86), and rapid decline in kidney function (OR, 1.25; 95% CI, 1.07, 1.47). Subgroup analyses showed a stronger association as the number of MetS components increased. However, gender-specific subgroups demonstrated varying associations.
UNASSIGNED: Metabolic syndrome is a significant risk factor for kidney dysfunction, requiring close renal monitoring. Lifestyle changes and targeted interventions may help reduce CKD burden. Further research is needed to understand the connection fully and assess intervention efficacy.
UNASSIGNED: The online version contains supplementary material available at 10.1007/s40200-023-01348-5.
摘要：
慢性肾脏病(CKD)是一个主要的全球健康问题，患病率和相关并发症不断增加。代谢综合征（MetS）与CKD有关，但是证据仍然不一致。我们进行了系统评价和荟萃分析，以研究MetS与肾功能障碍之间的关系。
■我们对数据库进行了全面搜索，直到2022年12月，用于评估MetS与事件肾功能障碍之间关联的队列研究。采用固定效应模型和随机效应模型进行Meta分析。进行亚组分析以探索异质性。使用Egger和Begg测试评估出版偏倚。
■共有24项符合条件的研究，涉及6,573,911名参与者，纳入本荟萃分析。MetS与发展为CKD的风险增加显著相关(OR，1.42；95%CI，1.28，1.57），白蛋白尿或蛋白尿(OR，1.43；95%CI，1.10，1.86），和肾功能迅速下降(OR，1.25；95%CI，1.07，1.47）。亚组分析显示，随着MetS成分数量的增加，相关性更强。然而,性别特异性亚组表现出不同的关联.
■代谢综合征是肾功能不全的重要危险因素，需要密切肾脏监测.生活方式的改变和有针对性的干预措施可能有助于减轻CKD负担。需要进一步的研究来充分了解这种联系并评估干预效果。
■在线版本包含补充材料，可在10.1007/s40200-023-01348-5获得。
■我们对数据库进行了全面搜索，直到2022年12月，用于评估MetS与事件肾功能障碍之间关联的队列研究。采用固定效应模型和随机效应模型进行Meta分析。进行亚组分析以探索异质性。使用Egger和Begg测试评估出版偏倚。
■共有24项符合条件的研究，涉及6,573,911名参与者，纳入本荟萃分析。MetS与发展为CKD的风险增加显著相关(OR，1.42；95%CI，1.28，1.57），白蛋白尿或蛋白尿(OR，1.43；95%CI，1.10，1.86），和肾功能迅速下降(OR，1.25；95%CI，1.07，1.47）。亚组分析显示，随着MetS成分数量的增加，相关性更强。然而,性别特异性亚组表现出不同的关联.
■代谢综合征是肾功能不全的重要危险因素，需要密切肾脏监测.生活方式的改变和有针对性的干预措施可能有助于减轻CKD负担。需要进一步的研究来充分了解这种联系并评估干预效果。
■在线版本包含补充材料，可在10.1007/s40200-023-01348-5获得。
